Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease

Hidekazu Suzuki, Tatsuhiro Masaoka, Sachiko Nomura, Yoshinori Hoshino, Kumiko Kurabayashi, Yuriko Minegishi, Masayuki Suzuki, Hiromasa Ishii

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Helicobacter pylori (H. pylori) is a spiral shaped bacterium that resides in the stomach mucosa. Isolation of H. pylori from the stomach mucosa changed the erstwhile widely held belief that the stomach contains no bacteria and is actually sterile. Once H. pylori is safely ensconced in the mucus, it is able to neutralize the acid in the stomach by elaborating an enzyme called urease. Urease converts urea, of which there is an abundant supply in the stomach (derived from saliva and the gastric juice), into bicarbonate and ammonia, which are strong bases. These bases form a cloud of acid-neutralizing chemicals in the vicinity of the organisms, protecting them from the acid in the stomach. This urea hydrolysis reaction is utilized for the diagnosis of H. pylori infection in the urea breath test (UBT) and the rapid urease test (RUT). In Japan, both invasive tests, such as bacterial culture, histopathology and RUT, and non-invasive tests such as UBT and serology are conducted for the diagnosis of H. pylori infection. For confirming the results of eradication therapy, UBT is considered to be the most sensitive and specific. In order to treat H. pylori infection, a new one-week triple therapy regimen (lansoprazole or omeprazole + amoxicillin + clarithromycin) has been approved for use in patients with peptic ulcer disease in Japan. As for H. pylori eradication in the case of other diseases in which the bacterium has been implicated (e.g., chronic atrophic gastritis, gastric MALT lymphoma, gastric cancer, non-ulcer dyspepsia, chronic urticaria, idiopathic thrombocytopenic purpura (ITP)), further basic and clinical investigation is required.

Original languageEnglish
Pages (from-to)163-173
Number of pages11
JournalKeio Journal of Medicine
Volume52
Issue number3
Publication statusPublished - 2003 Sep

Fingerprint

Helicobacter pylori
Stomach
Urease
Urea
Breath Tests
Helicobacter Infections
Bacteria
Therapeutics
Acids
Japan
Mucous Membrane
Lansoprazole
Atrophic Gastritis
Marginal Zone B-Cell Lymphoma
Gastric Juice
Idiopathic Thrombocytopenic Purpura
Clarithromycin
Omeprazole
Dyspepsia
Amoxicillin

Keywords

  • Apoptosis
  • Rapid urease test
  • Triple therapy
  • Urea breath test
  • Urease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Suzuki, H., Masaoka, T., Nomura, S., Hoshino, Y., Kurabayashi, K., Minegishi, Y., ... Ishii, H. (2003). Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease. Keio Journal of Medicine, 52(3), 163-173.

Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease. / Suzuki, Hidekazu; Masaoka, Tatsuhiro; Nomura, Sachiko; Hoshino, Yoshinori; Kurabayashi, Kumiko; Minegishi, Yuriko; Suzuki, Masayuki; Ishii, Hiromasa.

In: Keio Journal of Medicine, Vol. 52, No. 3, 09.2003, p. 163-173.

Research output: Contribution to journalArticle

Suzuki, H, Masaoka, T, Nomura, S, Hoshino, Y, Kurabayashi, K, Minegishi, Y, Suzuki, M & Ishii, H 2003, 'Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease', Keio Journal of Medicine, vol. 52, no. 3, pp. 163-173.
Suzuki H, Masaoka T, Nomura S, Hoshino Y, Kurabayashi K, Minegishi Y et al. Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease. Keio Journal of Medicine. 2003 Sep;52(3):163-173.
Suzuki, Hidekazu ; Masaoka, Tatsuhiro ; Nomura, Sachiko ; Hoshino, Yoshinori ; Kurabayashi, Kumiko ; Minegishi, Yuriko ; Suzuki, Masayuki ; Ishii, Hiromasa. / Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease. In: Keio Journal of Medicine. 2003 ; Vol. 52, No. 3. pp. 163-173.
@article{46d54eba6c0148efbba1b29a34636da7,
title = "Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease",
abstract = "Helicobacter pylori (H. pylori) is a spiral shaped bacterium that resides in the stomach mucosa. Isolation of H. pylori from the stomach mucosa changed the erstwhile widely held belief that the stomach contains no bacteria and is actually sterile. Once H. pylori is safely ensconced in the mucus, it is able to neutralize the acid in the stomach by elaborating an enzyme called urease. Urease converts urea, of which there is an abundant supply in the stomach (derived from saliva and the gastric juice), into bicarbonate and ammonia, which are strong bases. These bases form a cloud of acid-neutralizing chemicals in the vicinity of the organisms, protecting them from the acid in the stomach. This urea hydrolysis reaction is utilized for the diagnosis of H. pylori infection in the urea breath test (UBT) and the rapid urease test (RUT). In Japan, both invasive tests, such as bacterial culture, histopathology and RUT, and non-invasive tests such as UBT and serology are conducted for the diagnosis of H. pylori infection. For confirming the results of eradication therapy, UBT is considered to be the most sensitive and specific. In order to treat H. pylori infection, a new one-week triple therapy regimen (lansoprazole or omeprazole + amoxicillin + clarithromycin) has been approved for use in patients with peptic ulcer disease in Japan. As for H. pylori eradication in the case of other diseases in which the bacterium has been implicated (e.g., chronic atrophic gastritis, gastric MALT lymphoma, gastric cancer, non-ulcer dyspepsia, chronic urticaria, idiopathic thrombocytopenic purpura (ITP)), further basic and clinical investigation is required.",
keywords = "Apoptosis, Rapid urease test, Triple therapy, Urea breath test, Urease",
author = "Hidekazu Suzuki and Tatsuhiro Masaoka and Sachiko Nomura and Yoshinori Hoshino and Kumiko Kurabayashi and Yuriko Minegishi and Masayuki Suzuki and Hiromasa Ishii",
year = "2003",
month = "9",
language = "English",
volume = "52",
pages = "163--173",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "3",

}

TY - JOUR

T1 - Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease

AU - Suzuki, Hidekazu

AU - Masaoka, Tatsuhiro

AU - Nomura, Sachiko

AU - Hoshino, Yoshinori

AU - Kurabayashi, Kumiko

AU - Minegishi, Yuriko

AU - Suzuki, Masayuki

AU - Ishii, Hiromasa

PY - 2003/9

Y1 - 2003/9

N2 - Helicobacter pylori (H. pylori) is a spiral shaped bacterium that resides in the stomach mucosa. Isolation of H. pylori from the stomach mucosa changed the erstwhile widely held belief that the stomach contains no bacteria and is actually sterile. Once H. pylori is safely ensconced in the mucus, it is able to neutralize the acid in the stomach by elaborating an enzyme called urease. Urease converts urea, of which there is an abundant supply in the stomach (derived from saliva and the gastric juice), into bicarbonate and ammonia, which are strong bases. These bases form a cloud of acid-neutralizing chemicals in the vicinity of the organisms, protecting them from the acid in the stomach. This urea hydrolysis reaction is utilized for the diagnosis of H. pylori infection in the urea breath test (UBT) and the rapid urease test (RUT). In Japan, both invasive tests, such as bacterial culture, histopathology and RUT, and non-invasive tests such as UBT and serology are conducted for the diagnosis of H. pylori infection. For confirming the results of eradication therapy, UBT is considered to be the most sensitive and specific. In order to treat H. pylori infection, a new one-week triple therapy regimen (lansoprazole or omeprazole + amoxicillin + clarithromycin) has been approved for use in patients with peptic ulcer disease in Japan. As for H. pylori eradication in the case of other diseases in which the bacterium has been implicated (e.g., chronic atrophic gastritis, gastric MALT lymphoma, gastric cancer, non-ulcer dyspepsia, chronic urticaria, idiopathic thrombocytopenic purpura (ITP)), further basic and clinical investigation is required.

AB - Helicobacter pylori (H. pylori) is a spiral shaped bacterium that resides in the stomach mucosa. Isolation of H. pylori from the stomach mucosa changed the erstwhile widely held belief that the stomach contains no bacteria and is actually sterile. Once H. pylori is safely ensconced in the mucus, it is able to neutralize the acid in the stomach by elaborating an enzyme called urease. Urease converts urea, of which there is an abundant supply in the stomach (derived from saliva and the gastric juice), into bicarbonate and ammonia, which are strong bases. These bases form a cloud of acid-neutralizing chemicals in the vicinity of the organisms, protecting them from the acid in the stomach. This urea hydrolysis reaction is utilized for the diagnosis of H. pylori infection in the urea breath test (UBT) and the rapid urease test (RUT). In Japan, both invasive tests, such as bacterial culture, histopathology and RUT, and non-invasive tests such as UBT and serology are conducted for the diagnosis of H. pylori infection. For confirming the results of eradication therapy, UBT is considered to be the most sensitive and specific. In order to treat H. pylori infection, a new one-week triple therapy regimen (lansoprazole or omeprazole + amoxicillin + clarithromycin) has been approved for use in patients with peptic ulcer disease in Japan. As for H. pylori eradication in the case of other diseases in which the bacterium has been implicated (e.g., chronic atrophic gastritis, gastric MALT lymphoma, gastric cancer, non-ulcer dyspepsia, chronic urticaria, idiopathic thrombocytopenic purpura (ITP)), further basic and clinical investigation is required.

KW - Apoptosis

KW - Rapid urease test

KW - Triple therapy

KW - Urea breath test

KW - Urease

UR - http://www.scopus.com/inward/record.url?scp=0141867803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141867803&partnerID=8YFLogxK

M3 - Article

C2 - 14529149

AN - SCOPUS:0141867803

VL - 52

SP - 163

EP - 173

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 3

ER -